GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Debt-to-Revenue

Oncodesign Precision Medicine (XPAR:ALOPM) Debt-to-Revenue : 13.50 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Oncodesign Precision Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Oncodesign Precision Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €8.83 Mil. Oncodesign Precision Medicine's annualized Revenue for the quarter that ended in Dec. 2023 was €0.65 Mil. Oncodesign Precision Medicine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 13.50.

Oncodesign Precision Medicine Debt-to-Revenue Historical Data

The historical data trend for Oncodesign Precision Medicine's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Debt-to-Revenue Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
0.71 0.76 0.33 8.23

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial 3.06 0.17 1.66 13.50 -

Competitive Comparison of Oncodesign Precision Medicine's Debt-to-Revenue

For the Biotechnology subindustry, Oncodesign Precision Medicine's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Debt-to-Revenue falls into.


;
;

Oncodesign Precision Medicine Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Oncodesign Precision Medicine's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 8.827) / 1.072
=8.23

Oncodesign Precision Medicine's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 8.827) / 0.654
=13.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Oncodesign Precision Medicine Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Debt-to-Revenue
Comparable Companies
XPAR:ALTAO XPAR:ALTME XPAR:ALVET XPAR:ALVIO XPAR:ALINT XPAR:ALTHX XPAR:ALBPS XPAR:ALPAT XPAR:GNRO XPAR:ALMDP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines